tbuckley/cabot-search huggingface dataset:
Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)
Authors: Jesus G. Berdeja, Francisco Hernandez-Ilizaliturri, Asher Chanan-Khan, Manish Patel, Kevin R. Kelly, Kelli L. Running, Mary Murphy, Robin Guild, Christina Carrigan, Sharron Ladd, Beni B. Wolf, James J. O'Leary, Sikander Ailawadhi
Journal: Blood (2012)
Natural Killer Cells Transfer Antimicrobial and Antitumoral Histone H2AZ to Kill Multiple Myeloma Cells Contributing to Transmissible Cytotoxicity
Authors: Beatriz Martin-Antonio, Guillermo Suñe, Amer Najjar, Lorena Perez-Amill, Maria Velasco-de Andres, Francisco Lozano, Ester Lozano, Cristina Muñoz-Punedo, Carlos Fernández de Larrea, Alvaro Urbano-Ispizua
Journal: Blood (2016)
Phase 1 to 3 of the update of the EORTC Quality of Life Gastric module QLQ-STO22
Authors: Mitsumi Terada, Samantha Sodergren, Jane Blazeby, Susanne Singer, Takaki Yoshikawa, Masanori Terashima, Florian Lordick, Vassilios Vassiliou
Journal: Annals of Oncology (2019)
Specific Deletion of Keap1 in Endothelial Cells or/and Macrophages of SCD Mice Induces Nrf2 to Protect Tissues Against Oxidative Insults
Authors: Nadine Keleku-Lukwete, Panda Harit, Eriko Naganuma, Mikiko Suzuki, Masayuki Yamamoto
Journal: Blood (2016)
EBV-Encoded Mirnas Facilitate Inflammation and Tumor Formation Through Both Intra- and Inter-Cellular Regulation In Vivo Mouse Model
Authors: Natsuko Yamakawa, Jun Ogata, Takashi Yahata, Jun Lu, Kazuaki Yokoyama, Kiyoshi Ando, Naoya Nakamura, Ai Kotani
Journal: Blood (2013)
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial
Authors: Yong Sang Hong, Sun Young Kim, Ji Sung Lee, Byung-Ho Nam, Kyu-pyo Kim, Jeong Eun Kim, Young Suk Park, Joon Oh Park, Ji Yeon Baek, Tae-You Kim, Keun-Wook Lee, Joong Bae Ahn, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim, Seong Hyeon Yun, Jong Hoon Kim, Jin-hong Park, Hee Chul Park, Kyung Hae Jung, Tae Won Kim
Journal: Journal of Clinical Oncology (2019)

PURPOSE We evaluated the role of oxaliplatin as adjuvant chemotherapy in patients with rectal cancer who received preoperative chemoradiotherapy (CRT) with fluoropyrimidine monotherapy and total mesorectal excision (TME). METHODS The ADORE trial (adjuvant oxaliplatin in rectal cancer) is a multicenter, randomized trial in patients with postoperative ypStage II (ypT3-4N0) or III (ypT any N1-2) rectal cancer after fluoropyrimidine-based preoperative CRT and TME. Patients were randomly assigned (1:1) to receive adjuvant chemotherapy either with FL (fluorouracil 380 mg/m 2 and leucovorin 20 mg/m 2 ) or FOLFOX (oxaliplatin 85 mg/m 2 , leucovorin 200 mg/m 2 , and fluorouracil bolus 400 mg/m 2 on day 1, fluorouracil infusion 2,400 mg/m 2 for 46 hours). Stratification factors included ypStage and participating center. Primary end point was disease-free survival (DFS). RESULTS A total of 321 patients were enrolled between November 19, 2008, and June 12, 2012. Six-year DFS rates were 68.2% in the FOLFOX arm versus 56.8% in the FL arm, with a stratified hazard ratio of 0.63 (95% CI, 0.43 to 0.93; P = .018) by intention-to-treat analysis. In the subgroup analysis for DFS, FOLFOX was favorable versus FL in patients with ypStage III, ypN1b, ypN2, high-grade histology, minimally regressed tumor, and an absence of lymphovascular or perineural invasion. Six-year overall survival rate was 78.1% in the FOLFOX arm versus76.4% in the FL arm (hazard ratio, 0.73; 95% CI, 0.45 to 1.19; P = .21). In the subgroup analysis for OS, FOLFOX was favorable versus FL in patients with ypN2 and minimally regressed tumor. CONCLUSION Adjuvant FOLFOX improved DFS in patients with rectal cancer with ypStage II and III disease after preoperative CRT. Adjuvant FOLFOX may be considered on the basis of the postoperative pathologic stage in those who received preoperative CRT and TME.
Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.
Authors: Bart Barlogie, John D Shaughnessy, Elias Anaissie, Frits van Rhee, Yazan Alsayed, Sarah Waheed, Bijay Nair, Monica Grazziutti, Vanessa Bolejack, John Crowley
Journal: Blood (2009)
Chromatin remodelling to facilitate treatment resistance in glioblastoma
Authors: Alexander-F Bruns, Nora Rippaus, Alastair Droop, Muna Al-Jabri, Matthew Care, Michael Jenkinson, Andrew Brodbelt, Aruna Chakrabarty, Azzam Ismail, Susan Short, Lucy F Stead
Journal: Neuro-Oncology (2019)

Abstract Recent findings from our group, and the wider community, show that standard treatment does not impose an apparent bottleneck on the clonal evolution of adult glioblastoma (GBM), implying a lack of direct therapeutic opportunity. This does not negate the possibility that multiple treatment-resistance mechanisms co-exist in tumours, repeated across patients, making a combination of targeted therapies a potentially effective approach. We investigated whether treatment resistance may be driven by selection of cellular properties conferred above the level of the genome. Differential expression analysis was performed on 23 pairs of primary and recurrent tumours from patients who received standard treatment and had a local recurrence treated by surgery and second line chemotherapy. This revealed a treatment-induced shift in cell states linked to normal neurodevelopment. The latter is orchestrated by cascades of transcription factors. We, therefore, applied a bespoke gene set enrichment analysis to our paired expression data to investigate whether any factors were implicated in co-regulation of the genes that were altered through therapy. This identified a specific chromatin remodelling machinery, instrumental in normal neurogenesis. We validated our results in an independent cohort of 22 paired GBM samples. Our results suggest that the chromatin remodelling machinery is responsible for determining transcriptional hierarchies in GBM, shown elsewhere to have different treatment sensitivities such that their relative abundances are altered through treatment.
Altered Functional Properties of Eosinophils In Sickle Cell Anemia and Effects of Hydroxyurea Therapy
Authors: Flavia Rubia Pallis, Nicola Conran, Kleber Yotsumoto Fertrin, Sara T. Olalla-Saad, Fernando Ferreira Costa, Carla Fernanda Franco-Penteado
Journal: Blood (2010)
Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib.
Authors: Massimo Breccia, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Paola Volpicelli, Daniela Diverio, Roberto Latagliata, Giuliana Alimena
Journal: Blood (2012)
Characterization of Genomic Rearrangements Involving CIITA and SOCS1 Using Targeted Capture Sequencing of Archival Tissue Specimens
Authors: Anja Mottok, Lauren Chong, Susana Ben-Neriah, Bruce Woolcock, Yongjun Zhao, Marco A Marra, David W. Scott, Randy D. Gascoyne, Andrew J. Mungall, Christian Steidl
Journal: Blood (2016)
Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?
Authors: Roland Diel, Neil W. Schluger
Journal: European Respiratory Journal (2019)

<b>In patients with isoniazid-resistant tuberculosis, administering fluorochinolones may not be required if the duration of (H)RZE treatment is long enough (12 months), even with relatively short durations of Z in the initiation phase</b>http://bit.ly/2NjsCEQ
Evaluation of BRAFV600E, NRAS and KRAS Mutations As Well As IGHV Usage for Diagnostic Use in Hairy Cell Leukemia, Hairy Cell Leukemia-Variant and Splenic Marginal Zone Lymphoma.
Authors: Susanne Schnittger, Frank Dicker, Christiane Eder, Sabine Jeromin, Tamara Alpermann, Claudia Haferlach, Torsten Haferlach, Wolfgang Kern
Journal: Blood (2012)
Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database
Authors: Karim E Abou-Nassar, Ann Vanderplas, Jonathan W. Friedberg, Gregory Abel, Joyce Niland, Maria A. Rodriguez, Myron S. Czuczman, Michael Millenson, Allison Crosby, Leo I Gordon, Andrew D Zelenetz, Ann LaCasce
Journal: Blood (2010)
ICU staffing feature phenotypes and their relationship with patients’ outcomes: an unsupervised machine learning analysis
Authors: Fernando G. Zampieri, Jorge I. F. Salluh, Luciano C. P. Azevedo, Jeremy M. Kahn, Lucas P. Damiani, Lunna P. Borges, William N. Viana, Roberto Costa, Thiago D. Corrêa, Dieter E. S. Araya, Marcelo O. Maia, Marcus A. Ferez, Alexandre G. R. Carvalho, Marcos F. Knibel, Ulisses O. Melo, Marcelo S. Santino, Thiago Lisboa, Eliana B. Caser, Bruno A. M. P. Besen, Fernando A. Bozza, Derek C. Angus, Marcio Soares
Journal: Intensive Care Medicine (2019)
A Unique Immunotherapeutic Atrategy by Using a Leukemic Plasmacytoid Dendritic Cell Line (PMDC05) as Potent Antigen Presenting Cells.
Authors: Takeshi Nakamura, Miwako Narita, Akie Yamahira, Norihiro Watanabe, Nozomi Tochiki, Anri Saitoh, Masami Kaji, Tomoyo Taniguchi, Shigeo Hashimoto, Tatsuo Furukawa, Ken Toba, Ichiro Fuse, Yoshifusa Aizawa, Masuhiro Takahashi
Journal: Blood (2009)
Limited Feasibility of Double Transplant Program: A Multicenter Study on 151 Multiple Myeloma Patients Aged≤65 Years.
Authors: A. Corso, S. Mangiacavalli, L. Barbarano, E. P. Alessandrino, R. Cairoli, P. Zappasodi, D. Ferrari, A. Mazzone, S. Fava, M. Fiumanò, G. Frigerio, L. Isa, A. Luraschi, S. Montanara, M. Perego, M. Savarè, L. Uziel, A. Vismara, L. Campiotti, E. Morra, M. Lazzarino
Journal: Blood (2005)
Gain of CD20 Target Cell Surface Receptor Expression During Serum-Free Ex Vivo Culture of CD19+CD5+ B-Cells In a Sub-Population of Early Stage (Rai 0/1) Chronic Lymphocytic Leukemia Patients
Authors: Robin Frank, Hugo Jimenez, Sucheta Jagan, Lydia Luy Tan, Laura A Paganessi, Melissa L Larson, Parameswaran Venugopal, Stephanie A. Gregory, Kent W Christopherson
Journal: Blood (2010)
AML Genotype-Specific and Non-Specific Regulation of Mesenchymal Stromal Cell Transcriptome in the Bone Marrow Microenvironment
Authors: Rodrigo Jacamo, Xiaoyang Ling, Zhiqiang Wang, Wencai Ma, Min Zhang, Peter P. Ruvolo, Vivian R Ruvolo, Scott W. Lowe, Johannes Zuber, Marina Konopleva, R Eric Davis, Michael Andreeff
Journal: Blood (2014)
Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends
Authors: Irwin Walker, Aicha N Traore, Alfonso Iorio, Bruce Ritchie, Nancy Heddle, Kathryn E Webert, Jean St. Louis, David Lillicrap, Jerome M. Teitel, Anthony K.C. Chan
Journal: Blood (2012)
Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
Authors: Mikhail Fominykh, Vasily Shuvaev, Irina Martynkevich, Oleg Shukhov, Ekaterina Chelysheva, Anna G Turkina, Kudrat Abdulkadyrov
Journal: Blood (2016)
Specific Patterns of DNA Remethylation in the Bone Marrow Cells of Dnmt3a Deficient Mice after Induced Expression of Wild Type Human DNMT3A
Authors: Shamika Ketkar-Kulkarni, Angela Maria Verdoni, Nichole Helton, Christopher B Cole, Celia Venezia, Mieke Hoock, Catrina Fronick, Michelle O'Laughlin, Robert S. Fulton, David Spencer, Timothy J. Ley
Journal: Blood (2015)
Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease
Authors: Jennifer Whangbo, Bryn Falahee, John Koreth, Haesook T. Kim, Sarah Nikiforow, Vincent T. Ho, Corey S. Cutler, Philippe Armand, Edwin P. Alyea, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz
Journal: Blood (2016)
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Mediates and Sustains NF-κb Constitutive Activation in LGL Leukemia Cells
Authors: Jun Yang, Francis R Leblanc, Shubha Dighe, Susan B. Nyland, David J. Feith, Thomas P. Loughran
Journal: Blood (2016)
High Resolution Genome-Wide Copy Number Analysis of Pediatric Burkitt Lymphoma Identifies Copy Number Alterations In the Majority of Patients
Authors: Joshua D. Schiffman, Patrick D. Lorimer, Vladimir Rodic, Mona S. Jahromi, Jonathan M. Downie, Michael G. Bayerl, Sherrie L. Perkins, Phillip Barnette, Rodney R. Miles
Journal: Blood (2010)
High Intermittent Dose of Chlorambucil Associated with Rituximab Is a Promising Treatment of Elderly Patients with Indolent Lymphoma.
Authors: Laingo Andrianarison, Stephane Courby, Blandine Fabre, Lysiane Molina, Valerie Legrand, Brigitte Pegourie Bandelier, Audrey Simon, Clara Mariette, Claire Vettier, Christine Lefebvre, Frederic Garban, Claude Eric Bulabois, Anne Thiebaut, Jean Yves Cahn, Remy Gressin
Journal: Blood (2009)
Patterns of Clonal Evolution Assessed By Whole Exome Sequencing during Progression from MDS to AML Are Related to Therapy
Authors: María Abáigar, Jesús M Hernández-Sánchez, David Tamborero, Marta Martín-Izquierdo, María Díez-Campelo, María Hernández-Sánchez, Fernando Ramos, Marta Megido, Carlos Aguilar, Eva Lumbreras, Isabel Recio, Carmen Olivier, Cristina Robledo, Rocío Benito, Nuria Lopez-Bigas, Consuelo Del Cañizo, Jesús María Hernández-Rivas
Journal: Blood (2016)
Long-Term Follow up of Healthy Donors Receiving G-CSF for Peripheral Blood Progenitor Cell Mobilization and Collection.
Authors: Javier de la Rubia, Concha Zamora, Andres Insunza, Consuelo Cañizo, Cristina Arbona, Miguel A. Díaz, Felipe de Arriba, Carmen Paniagua, Dobleta Martínez, Miguel A. Sanz
Journal: Blood (2005)
Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States
Authors: Ruben Mesa, Carole B Miller, Maureen Thyne, James Mangan, Sara Goldberger, Salman Fazal, Xiaomei Ma, Wendy Wilson, David G Dubinski, John Boyle, John O Mascarenhas
Journal: Blood (2014)
A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531
Authors: Lisa Eidenschink Brodersen, Todd A. Alonzo, Andrew J. Menssen, Robert B. Gerbing, Laura Pardo, Andrew P. Voigt, Samir B. Kahwash, Betsy A. Hirsch, Susana C. Raimondi, Alan S. Gamis, Soheil Meshinchi, Michael R. Loken
Journal: Blood (2015)
Differential Dependence On Wnt Signaling Allows Chemical Mediated Eradication of Human Acute Leukemia without Affecting Normal Blood Stem Cells
Authors: Ruth M. Risueño, Eva Szabo, Uyen Maria Dang, Marilyne Levadoux-Martin, Jae-Uk Chung, Anargyros Xenocostas, Brian Leber, Mickie Bhatia
Journal: Blood (2010)
Pharmacological IGF1R/IRS Inhibitor, NT157, Effectively Induces Apoptosis and CDKN1A Expression in Acute Lymphoblastic Leukemia Cells
Authors: Ana Paula Nunes Rodrigues Alves, João Agostinho Machado-Neto, Jaqueline Cristina Fernandes, Bruna Alves Fenerich, Fernanda Borges da Silva, Priscila Santos Scheucher, Belinda Pinto Simões, Eduardo Magalhães Rego, Fabiola Traina
Journal: Blood (2016)
Graft Versus Host Disease Correlates with Increased Survival After Allogeneic Stem Cell Transplant for Mature T-Cell Lymphomas: Evidence of Graft Versus T-Cell Lymphoma Effect.
Authors: Maria L Delioukina, Joycelynne Palmer, Jasmine M. Zain, NC Tsai, Auayporn P. Nademanee, Stephen J Forman
Journal: Blood (2009)
BCR-ABL Specific Sequences Are Required To Prevent Ph+ Acute Lymphoblastic Leukemia in Syngeneic Mice by DNA Vaccination.
Authors: Joachim Köchling, Javier Prada, Masoud Bahrami, Sven A. König Merediz, Renata Stripecke, Karl Seeger, Günter Henze, Burghardt Wittig, Manuel Schmidt
Journal: Blood (2006)
SET-NUP214 Fusion Gene at Chromosome 9q34 Contributed to the Development of Not Only T-ALL, but Also Primary and Secondary AML.
Authors: Myung-Geun Shin, Da-Woon Kim, Hye-Ran Kim, Duck Cho, Seung-Jung Kee, Soo-Hyun Kim, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang
Journal: Blood (2009)
IB1001, an Investigational Recombinant Factor IX, Pharmacokinetics in Pediatric Patients with Hemophilia B.
Authors: Edward D. Gomperts, Shashikant Apte, Utpal Chaudhuri, Joseph M John, Vijay Ramanan, Ri Liesner, Amy D. Shapiro, Bonnie J. Mills, Martin Lee
Journal: Blood (2012)
Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
Authors: Brandilyn A. Peters, Melissa Wilson, Una Moran, Anna Pavlick, Allison Izsak, Todd Wechter, Jeffrey S. Weber, Iman Osman, Jiyoung Ahn
Journal: Genome Medicine (2019)

Recent evidence suggests that immunotherapy efficacy in melanoma is modulated by gut microbiota. Few studies have examined this phenomenon in humans, and none have incorporated metatranscriptomics, important for determining expression of metagenomic functions in the microbial community.In melanoma patients undergoing immunotherapy, gut microbiome was characterized in pre-treatment stool using 16S rRNA gene and shotgun metagenome sequencing (n = 27). Transcriptional expression of metagenomic pathways was confirmed with metatranscriptome sequencing in a subset of 17. We examined associations of taxa and metagenomic pathways with progression-free survival (PFS) using 500 × 10-fold cross-validated elastic-net penalized Cox regression.Higher microbial community richness was associated with longer PFS in 16S and shotgun data (p < 0.05). Clustering based on overall microbiome composition divided patients into three groups with differing PFS; the low-risk group had 99% lower risk of progression than the high-risk group at any time during follow-up (p = 0.002). Among the species selected in regression, abundance of Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta were related to shorter PFS, and Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA to longer PFS. Metagenomic functions related to PFS that had correlated metatranscriptomic expression included risk-associated pathways of L-rhamnose degradation, guanosine nucleotide biosynthesis, and B vitamin biosynthesis.This work adds to the growing evidence that gut microbiota are related to immunotherapy outcomes, and identifies, for the first time, transcriptionally expressed metagenomic pathways related to PFS. Further research is warranted on microbial therapeutic targets to improve immunotherapy outcomes.
Mitigation of a Newly Discovered Phenomenon, Extra Physiologic Oxygen Shock/Stress (EPHOSS), Mediated By the Mitochondria Permeability Transition Pore, Greatly Improves Stem Cell Collection and Transplantation
Authors: Charlie Mantel, Heather A. O'Leary, Brahmananda Reddy Chitteti, Xinxin Huang, Scott Cooper, Giao Hangoc, Nickolay Brustovetsky, Edward F. Srour, Man Ryul Lee, Steven Messina-Graham, Nadia Falah, Reuben Kapur, Louis M. Pelus, Mircea Ivan, Kye-Seong Kim, Hal E. Broxmeyer
Journal: Blood (2014)
Loss of Mismatched HLA At Leukemia Relapse After Hematopoietic Stem Cell Transplantation Is Significantly Associated with Clinical and Immunogenetic Hallmarks of Donor-Versus-Host Alloreactivity
Authors: Lara Crucitti, Luca Vago, Roberto Crocchiolo, Cristina Toffalori, Maria Teresa Lupo Stanghellini, Andrea Assanelli, Matteo Carrabba, Benedetta Mazzi, Elisabetta Zino, Sarah Marktel, Magda Marcatti, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Claudio Bordignon, Chiara Bonini, Katharina Fleischhauer, Fabio Ciceri
Journal: Blood (2012)
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
Authors: Joyce F. Liu, Christina Herold, Kathryn P. Gray, Richard T. Penson, Neil Horowitz, Panagiotis A. Konstantinopoulos, Cesar M. Castro, Sarah J. Hill, Jennifer Curtis, Weixiu Luo, Ursula A. Matulonis, Stephen A. Cannistra, Don S. Dizon
Journal: JAMA Oncology (2019)

<h3>Importance</h3> To date, single-agent programmed cell death 1 protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint blockade has shown limited activity in recurrent epithelial ovarian cancer. Combination strategies of PD-1/PD-L1 inhibition with antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a potential therapeutic opportunity in this disease. <h3>Objective</h3> To evaluate the activity of combined nivolumab and bevacizumab in women with relapsed ovarian cancer. <h3>Design, Setting, and Participants</h3> A single-arm, phase 2 study enrolled patients between February 8, 2017, and December 29, 2017, at 2 sites in the United States; the primary data analysis was completed July 27, 2018. Thirty-eight women with relapsed epithelial ovarian cancer were enrolled in this study. Participants had disease recurrence within 12 months of their last platinum-based therapy and had received between 1 and 3 lines of prior therapy. <h3>Interventions</h3> Participants received intravenous nivolumab and intravenous bevacizumab once every 2 weeks. <h3>Main Outcome and Measures</h3> The primary end point was objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors 1.1. Secondary end points included evaluation of the ORR by platinum sensitivity, assessment of progression-free survival, assessment of safety data, and investigation of the association of tumor PD-L1 with response to therapy. <h3>Results</h3> Of the 38 women enrolled, 18 had platinum-resistant and 20 had platinum-sensitive disease; mean (SD) age was 63.0 (9.1) years. Eleven patients experienced a confirmed response to nivolumab with bevacizumab (ORR, 28.9%; 95% exact binomial CI, 15.4%-45.9%), with 1 additional unconfirmed response. The ORR was 40.0% (19.1%-64.0%) in platinum-sensitive and 16.7% (95% CI 3.6%-41.4%) in platinum-resistant participants. Thirty-four participants (89.5%) experienced at least 1 treatment-related adverse event; 9 participants (23.7%) experienced a grade 3 or higher treatment-related adverse event. Median progression-free survival was 8.1 months (95% CI, 6.3-14.7 months). In 36 histologic samples for which PD-L1 testing could be performed, 22 samples (61.1%) had a PD-L1 tumoral percentage less than 1, and 14 samples (38.9%) had a PD-L1 tumoral percentage of 1 or greater. Ten responses occurred in patients with PD-L1 tumor percentage less than 1, and 2 in patients with PD-L1 tumor percentages of 1 or greater. <h3>Conclusions and Relevance</h3> The nivolumab with bevacizumab combination appeared to show activity in patients with relapsed ovarian cancer, with greater activity in the platinum-sensitive setting. Alternative combinational strategies may be necessary in the platinum-resistant setting.
Clinical outcome of salvage chemotherapy after oxaliplatin based chemotherapy for metastatic small bowel adenocarcinoma
Authors: Yoshitaka Homma, Hidekazu Hirano, Hirokazu Shoji, Natsuko Okita, Satoru Iwasa, Atsuo Takashima, Ken Kato, Narikazu Boku
Journal: Annals of Oncology (2019)
The Arginine-to-Ornithine Ratio: Biomarker of Arginase Activity and Predictor of Mortality in Sickle Cell Disease.
Authors: Claudia R. Morris, Gregory Kato, Mirjana Poljakovic, William C. Blackwelder, Stan Hazen, Elliott P. Vichinsky, Sidney M. Morris, Mark T. Gladwin
Journal: Blood (2004)
Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents
Authors: Gee Youn (Geeny) Kim, Jonathan Burns, Craig W. Freyer, Keith Hamilton, Mindy Schuster, Noelle V. Frey, Elizabeth O. Hexner, James K. Mangan, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, David L. Porter, Selina Luger, Alison W. Loren
Journal: Blood (2018)
A Single-Center Retrospective Study of 140 Patients with Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation
Authors: Michael D Jain, Ryan Lam, Rashmi S Goswami, Krystyna Tybinkowski, Parneet K Cheema, Atul Humar, Richard Tsang, David Hodgson, Anca Prica, Vishal Kukreti, Michael Crump, John Kuruvilla
Journal: Blood (2016)